Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aligos Therapeutics, Inc.ALGS · Entity 7352 | Chief Medical Officer | March 01, 2024 | March 04, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aligos Therapeutics, Inc.
Report date March 01, 2024 · Filed March 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.13 · Expires 2034-03-01 | Direct | 72,000 |
Reported balance
After 2024-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-01 · Grant · Acquired 72,000 · Balance 72,000 F1: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 1, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 1, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2024 Filed Mar 4, 2024 17:44 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 72,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001610717-24-000124 · form4.xml · derivative · entry 1 McClure Matthew W. · CIK 0001927121 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 72,000 shares Expires 2034-03-01 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 1, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 17:33 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 16,428 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001610717-24-000100 · form4.xml · derivative · entry 6 McClure Matthew W. · CIK 0001927121 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,428 Underlying: Common Stock · 16,428 shares Expires 2032-02-04 F3 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 23,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 16,428 shares, having an exercise price of $0.96 per share. F4 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 17:33 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 65,713 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001610717-24-000100 · form4.xml · derivative · entry 5 McClure Matthew W. · CIK 0001927121 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,713 Underlying: Common Stock · 65,713 shares Expires 2032-02-04 F2 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 92,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 65,713 shares, having an exercise price of $0.96 per share. F5 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 75% of the total number of shares subject to the option on the one year anniversary of the date of the grant and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the reporting person's continued service with the issuer on each such vesting date. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 17:33 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 75,183 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001610717-24-000100 · form4.xml · derivative · entry 4 McClure Matthew W. · CIK 0001927121 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,183 Underlying: Common Stock · 75,183 shares Expires 2030-12-01 F1 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 255,626 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 75,183 shares, having an exercise price of $0.96 per share. F4 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 17:33 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | Disposition to issuerStock Option (Right to Buy) · Derivative | 23,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001610717-24-000100 · form4.xml · derivative · entry 3 McClure Matthew W. · CIK 0001927121 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,000 shares Expires 2032-02-04 F3 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 23,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 16,428 shares, having an exercise price of $0.96 per share. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 17:33 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | Disposition to issuerStock Option (Right to Buy) · Derivative | 92,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001610717-24-000100 · form4.xml · derivative · entry 2 McClure Matthew W. · CIK 0001927121 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 92,000 shares Expires 2032-02-04 F2 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 92,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 65,713 shares, having an exercise price of $0.96 per share. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 17:33 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | Disposition to issuerStock Option (Right to Buy) · Derivative | 255,626 | $0.00 Strike: $16.18 | $0.00 |
DisclosureSEC source: 0001610717-24-000100 · form4.xml · derivative · entry 1 McClure Matthew W. · CIK 0001927121 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 255,626 shares Expires 2030-12-01 F1 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 255,626 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 75,183 shares, having an exercise price of $0.96 per share. Read SEC document |
| September 08, 2023 Filed Sep 12, 2023 16:08 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 48,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001610717-23-000277 · form4.xml · derivative · entry 1 McClure Matthew W. · CIK 0001927121 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2033-09-08 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 20, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 16:12 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001567619-23-005257 · doc1.xml · derivative · entry 1 McClure Matthew W. · CIK 0001927121 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-03-15 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 15, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 16:15 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 46,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001567619-22-013870 · doc1.xml · derivative · entry 1 McClure Matthew W. · CIK 0001927121 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,000 Underlying: Common Stock · 46,000 shares Expires 2032-07-07 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 7, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.